Sponsor or institution

Clinical trials and research at Novartis

• 181Clinical trials
• 1New in 30 days
• 68Countries

Newest trials

All recruiting trials (newest 150 of 181)

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Dose-finding test of YMI024 in adults with stable coronary artery disease and high hsCRP

  This study tests several doses of YMI024 to see if it reduces inflammation and is safe for adults with stable CAD and elevated hsCRP, compared to placebo.

  Recruiting at 23 sites Phase 2 Novartis · Fairhope, Alabama and 22 other locations · NCT07830719

• Remibrutinib and omalizumab-based treatment approach for adults with chronic spontaneous urticaria not well controlled by antihistamines

  This trial tests a sequencing plan using remibrutinib and omalizumab to see if it helps adults with chronic spontaneous urticaria that isn’t well controlled by second-generation antihistamines.

  Recruiting at 10 sites Phase 3 Novartis · London, Ontario and 9 other locations · NCT07816328

• Single-dose combination therapy for uncomplicated malaria in young children

  This study tests whether a single oral dose of a combination of anti-malarial drugs can cure uncomplicated Plasmodium falciparum malaria in children aged 2 to under 12 years, compared with standard Coartem treatment.

  Recruiting at 5 sites Phase 2 Novartis · Banfora and 12 other locations · NCT07811908

• Remibrutinib for Severe Chronic Pruritus of Unknown Origin in Adults

  We’re testing whether remibrutinib can help adults with severe, unexplained itching that hasn’t gone away with moisturizers.

  Recruiting at 12 sites Phase 3 Novartis · Fremont, California and 11 other locations · NCT07811869

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• DDY391 in psoriatic arthritis: a mid-stage test in adults with active disease

  This Phase 2 study tests whether DDY391 can help adults with moderate to severe psoriatic arthritis and what dose works best.

  Recruiting at 8 sites Phase 2 Novartis · Huntington Beach, California and 7 other locations · NCT07801495

• PKN605 in people with kidney problems and in healthy volunteers

  This phase 1 study tests how PKN605 behaves in the body and its safety in adults with moderate or severe kidney impairment compared with healthy adults.

  Recruiting at 3 sites Phase 1 Novartis · Miami, Florida and 2 other locations · NCT07797322

• What patients with primary ITP prefer in their treatment

  This survey-based study in the US will ask adults with primary ITP about which treatment options they prefer and why.

  Recruiting Novartis · East Hanover, New Jersey · NCT07786077

• Pelabresib interaction with phenytoin and itraconazole in healthy adults

  This study tests how phenytoin or itraconazole affect the way pelabresib behaves in the body after a single dose in healthy adults.

  Recruiting Phase 1 Novartis · Nottingham · NCT07783503

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• GIA632 for moderate to severe cutaneous lichen planus: how well it works and is safe across doses

  This study tests different doses of GIA632 to see if it can safely improve skin symptoms in adults with moderate to severe cutaneous lichen planus who have not had full control with topical treatments.

  Recruiting at 27 sites Phase 2 Novartis · Birmingham, Alabama and 26 other locations · NCT07775924

• Remibrutinib for IgE-mediated peanut, milk, and egg allergy

  This study tests whether remibrutinib can help people with peanut, milk, or egg allergies by comparing it to placebo over 52 weeks.

  Recruiting at 22 sites Phase 3 Novartis · Birmingham, Alabama and 21 other locations · NCT07768371

• Intrathecal Zolgensma in spinal muscular atrophy patients in Japan

  This study tests the safety and real‑world effectiveness of intrathecal onasemnogene abeparvovec in SMA patients in Japan.

  Recruiting at 4 sites Novartis · Toyoake, Aichi-ken and 3 other locations · NCT07767890

• Arumakimig (MAS825) in VEXAS syndrome: 52 weeks to see if it helps people on steroids

  This study tests whether arumakimig can help adults with VEXAS syndrome who are taking glucocorticoids, compared with a placebo, over a year (with an option for a long-term extension).

  Recruiting at 6 sites Phase 2 Novartis · Yokohama, Kanagawa and 5 other locations · NCT07748624

• DDY391 in Sjögren's disease: see if it works and is safe

  This study tests whether DDY391 is effective and safe for people with Sjögren's disease over up to 52 weeks.

  Recruiting at 31 sites Phase 2 Novartis · Avondale, Arizona and 30 other locations · NCT07737743

• Understanding how Cryptosporidium shows up in kids with diarrhea

  This observational study in young children with diarrhea tests how Cryptosporidium presents and behaves in real-world settings.

  Recruiting at 4 sites Novartis · Kisumu, Nyanza and 3 other locations · NCT07716410

• Remibrutinib for Severe Chronic Pruritus of Unknown Origin

  This study tests whether remibrutinib can help adults with severe CPUO see if their itch improves compared with a placebo.

  Recruiting at 24 sites Phase 3 Novartis · Cullman, Alabama and 23 other locations · NCT07700056

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Remibrutinib for moderate-to-severe papulopustular rosacea

  A Phase 2 study tests whether remibrutinib can reduce inflammatory facial lesions in adults with moderate-to-severe papulopustular rosacea.

  Recruiting at 17 sites Phase 2 Novartis · El Paso, Texas and 16 other locations · NCT07681271

• Real-world patterns and outcomes for mCRPC patients who have had ARPI, taxane, and 177Lu-PSMA-617

  This real-world study tests how patients with metastatic castration-resistant prostate cancer, who have already received an ARPI, a taxane, and 177Lu-PSMA-617, fare in US practice using PRECISION data.

  Recruiting Novartis · East Hanover, New Jersey · NCT07677267

• Real-world patterns and outcomes in metastatic castration-resistant prostate cancer

  This study tests how patients with metastatic castration-resistant prostate cancer are treated and how they fare in real-world U.S. practice using the PRECISION data platform.

  Recruiting Novartis · East Hanover, New Jersey · NCT07677254

• Remibrutinib extension study for adults with moderate to severe hidradenitis suppurativa

  This extension study tests whether continuing remibrutinib is safe and helps skin symptoms in adults who completed prior HS trials.

  Recruiting at 61 sites Phase 3 Novartis · Birmingham, Alabama and 60 other locations · NCT07665437

• Targeted radioligand therapy for several solid tumors using DWJ155 imaging and treatment

  A phase 1 study tests [177Lu]Lu-DWJ155 for treatment and [68Ga]Ga-DWJ155 for imaging in adults with certain breast cancers, NSCLC, GEJ cancer, or bladder cancer who have not benefited from standard therapies.

  Recruiting at 6 sites Phase 1 Novartis · Omaha, Nebraska and 5 other locations · NCT07660055

• HJB647 in Japanese adults with elevated blood pressure and hypertension

  This study tests safety, tolerability, and how the body handles HJB647 after single and multiple doses in Japanese adults with elevated blood pressure and in patients with hypertension.

  Recruiting Phase 1 Novartis · Sumida Ku, Tokyo · NCT07644364

• Remibrutinib in real-world care for Chronic Spontaneous Urticaria in Germany

  This study looks at how well and how safely remibrutinib works for adults with chronic spontaneous urticaria in real clinical practice after doctors decide to switch or escalate treatment.

  Recruiting Novartis · Düren · NCT07642557

• GEP-NET treatment patterns and outcomes in the U.S.

  This study will see how newly diagnosed GEP-NET patients are treated in real-world settings and what their outcomes look like.

  Recruiting Novartis · East Hanover, New Jersey · NCT07635316

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

• Safety and PK/PD of a new inclisiran formulation with polysorbate 80 vs the marketed version in healthy adults

  This study tests a new inclisiran formulation containing polysorbate 80 to see if it is as safe and tolerable as the current version after a single injection in healthy adults with elevated LDL-C.

  Recruiting at 6 sites Phase 1 Novartis · Lenexa, Kansas and 5 other locations · NCT07626281

• Ianalumab vs placebo in adults with Sjögren's disease and high symptom burden

  A 52-week study will test whether monthly 300 mg ianalumab injections help adults with Sjögren's disease who have high symptom burden.

  Recruiting at 72 sites Phase 3 Novartis · Peoria, Arizona and 71 other locations · NCT07621809

• Combination therapy with QCZ484 and Inclisiran for hypertension with high cholesterol

  This study tests whether the drug QCZ484, alone or with Inclisiran, lowers cholesterol and helps blood pressure in adults with hypertension and high cholesterol.

  Recruiting at 29 sites Phase 2 Novartis · Foley, Alabama and 28 other locations · NCT07610278

• IEV407 as a single agent or with endocrine therapy for advanced HR+/HER2- breast cancer

  This study tests IEV407 by itself and with fulvestrant or letrozole to see if it is safe and shows signs of activity in adults with advanced HR+/HER2- breast cancer.

  Recruiting at 12 sites Phase 1 Novartis · New Haven, Connecticut and 11 other locations · NCT07604571

• First-in-human test of DCY636 in healthy adults and in people with moderate to severe atopic dermatitis

  This study will test whether DCY636 is safe and tolerated in healthy adults and whether it can be safely given to people with moderate to severe atopic dermatitis.

  Recruiting Phase 1 Novartis · Fukuoka · NCT07604324

• Iptacopan for Adult C3 Glomerulopathy in Spain

  This is an observational program in Spain looking at adults with C3G who have received iptacopan through an early access program to see real-world experiences.

  Recruiting at 2 sites Novartis · Córdoba and 1 other locations · NCT07598448

• Canakinumab use in Schnitzler’s syndrome in real-world patients

  This study tests how well and how safely canakinumab works for people diagnosed with Schnitzler’s syndrome who are taking it in routine clinical care.

  Recruiting at 5 sites Novartis · Kobe, Hyōgo and 4 other locations · NCT07598422

• Ruxolitinib for Graft-Versus-Host Disease in Clinical Practice

  This study tests how well Jakavi (ruxolitinib) works and how safe it is for people with acute or chronic GVHD being treated in real-world medical settings.

  Recruiting Novartis · Tokyo · NCT07594587

• Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

  This study looks at how eltrombopag is used in adult patients with primary ITP and what outcomes are seen in routine care.

  Recruiting Novartis · Basel · NCT07587723

• Oral INR731 alone or with androgen receptor blockers for metastatic castration-resistant prostate cancer

  This tests whether oral INR731 by itself or with androgen receptor pathway inhibitors is safe, tolerable, and shows early anti‑tumor activity in adults with metastatic castration‑resistant prostate cancer.

  Recruiting at 13 sites Phase 1 Novartis · Boston, Massachusetts and 12 other locations · NCT07570979

• DJI136 CAR-T therapy for extensive-stage small cell lung cancer

  Researchers are testing DJI136, a CAR-T cell therapy, to see if it can help adults with extensive-stage small cell lung cancer who have already tried standard treatments.

  Recruiting at 7 sites Phase 1/2 Novartis · Lexington, Kentucky and 6 other locations · NCT07564401

• Asciminib for Ph+ CML-CP in Germany: real-world patient experiences

  This real-world study tests how asciminib performs in adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including those newly diagnosed or after one prior TKI.

  Recruiting at 74 sites Novartis · Baden-Baden, Baden-Wurttemberg and 73 other locations · NCT07549516

• Long-term use of inclisiran, evolocumab, and alirocumab in real-world care

  This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.

  Recruiting Novartis · Basel · NCT07543731

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

• QCZ484 extension for hypertensive patients after parent study

  This open-label extension tests long-term safety and effectiveness of QCZ484 given by injection every 6 months in people with hypertension who finished the parent study.

  Recruiting at 25 sites Phase 2 Novartis · Garden Grove, California and 24 other locations · NCT07543120

• Canakinumab use in FMF and Still's disease patients across real-world care

  This real-world study looks at how people with FMF or Still's disease who were treated with canakinumab fare over at least 6 months.

  Recruiting Novartis · Basel · NCT07517250

• Boosting Lp(a) testing in secondary care clinics

  This project will try different ways to increase Lp(a) blood testing for adults who attend hospital heart clinics so more people with high Lp(a) are found.

  Recruiting Novartis · Nuremberg · NCT07508007

• NIO752 treatment for people with Progressive Supranuclear Palsy Richardson syndrome.

  This trial will try NIO752 versus placebo in adults with mild-to-moderate PSP-RS to see if it slows symptom progression.

  Recruiting at 64 sites Phase 3 Novartis · Scottsdale, Arizona and 63 other locations · NCT07498426

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

• PULSE Registry: Lutetium-177Lu VIP (pluvict?), for patients with metastatic prostate cancer

  This registry will track how lutetium-177Lu vipivotide tetraxetan is used in real-world care for adults with metastatic prostate cancer.

  Recruiting Novartis · Basel · NCT07484269

• Real-world first-line treatments and outcomes for HR+/HER2- advanced breast cancer in China

  This project will look at real-world first-line treatment patterns and outcomes for adults in China with HR+/HER2- advanced or metastatic breast cancer, with a focus on use of CDK4/6 inhibitors such as ribociclib.

  Recruiting Novartis · Bingjie, Beijing Municipality · NCT07476170

• GXV813 for adults hospitalized with acute schizophrenia

  This trial will test whether the medication GXV813 helps adults hospitalized for an acute episode of schizophrenia and whether it is safe and well tolerated.

  Recruiting at 16 sites Phase 2 Novartis · Bentonville, Arkansas and 15 other locations · NCT07467993

• See if ARNi therapy helps people with high blood pressure in the UAE

  This real-world study tests whether sacubitril/valsartan (ARNi) or single-drug blood pressure medicine can lower blood pressure in adults with hypertension in the United Arab Emirates.

  Recruiting at 4 sites Novartis · Abu Dhabi and 3 other locations · NCT07465666

• HJB647 safety and tolerability in people with heart failure and reduced ejection fraction.

  This trial will test two doses of the experimental drug HJB647 versus placebo to see if it's safe and tolerated in adults with stable heart failure and reduced or mildly reduced ejection fraction who are already on sacubitril/valsartan.

  Recruiting at 6 sites Phase 1 Novartis · Bradenton, Florida and 5 other locations · NCT07465653

• Open-label roll-over access to remibrutinib

  This program continues remibrutinib treatment and monitors long-term safety for people who were already benefiting from remibrutinib in a Novartis study but cannot get it outside the study.

  Recruiting at 46 sites Phase 3 Novartis · Sofia and 45 other locations · NCT07456891

• Spinal muscular atrophy patients get a single intrathecal gene therapy dose to see how it works in real-world U.S. settings

  This study tests whether a one-time intrathecal dose of ITVISMA® (onasemnogene abeparvovec-brve) is safe and effective for SMA patients in real-world U.S. clinical practice.

  Recruiting at 6 sites Phase 4 Novartis · Little Rock, Arkansas and 5 other locations · NCT07448610

• FWY003 versus placebo for geographic atrophy from age-related macular degeneration

  This study will test whether injections of FWY003 can slow the growth of geographic atrophy in people aged 50 and older with AMD.

  Recruiting at 65 sites Phase 2 Novartis · Huntington Beach, California and 64 other locations · NCT07441642

• Different doses of GIA632 for adults with non-segmental vitiligo

  This trial tests whether different doses of GIA632 can safely help restore skin pigment in adults with non-segmental vitiligo.

  Recruiting at 85 sites Phase 2 Novartis · Birmingham, Alabama and 84 other locations · NCT07431177

• Pelabresib and liver function in adults with advanced cancer

  This tests how pelabresib is processed in the body at steady state in adults with advanced cancer who have normal or moderate-to-severe liver impairment.

  Recruiting at 10 sites Phase 1 Novartis · Bordeaux and 9 other locations · NCT07422610

• Ianalumab plus a thrombopoietin receptor agonist for adults with ITP or Evans syndrome

  This study will test whether adding ianalumab to a doctor's chosen TPO-RA is tolerable for adults with immune thrombocytopenia (and an exploratory group with Evans syndrome) who have had prior treatments and are on a stable TPO-RA dose.

  Recruiting at 23 sites Phase 2 Novartis · Chandler, Arizona and 22 other locations · NCT07421167

• Iptacopan use in Korean patients with PNH or C3G

  This post-marketing surveillance study tests how well iptacopan works and how safe it is for Korean adults with PNH or C3G in real-world care.

  Recruiting at 3 sites Novartis · Jeollanam and 2 other locations · NCT07416162

• Remibrutinib for adults with chronic spontaneous urticaria in routine care

  This prospective US study will see if remibrutinib helps adults with chronic spontaneous urticaria in real-world clinical practice using patient-reported outcome questionnaires.

  Recruiting Novartis · East Hanover, New Jersey · NCT07408219

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Characterizing secondary T‑cell cancers after tisagenlecleucel

  This will test tumor or blood samples from people who developed a T‑cell secondary cancer after receiving tisagenlecleucel to see if the CAR transgene or replication‑competent virus might be involved.

  Recruiting at 3 sites Novartis · Kurume, Fukuoka and 3 other locations · NCT07378969

• Scemblix (asciminib) for newly diagnosed chronic-phase CML in China

  This project will try asciminib (Scemblix) in adults newly diagnosed with chronic-phase CML to see if it controls the disease and is safe.

  Recruiting Novartis · Wuhan, Hubei · NCT07375355

• Remibrutinib use in everyday US care for chronic spontaneous urticaria

  This US sub-study will test remibrutinib's real-world safety and effectiveness for adults with chronic spontaneous urticaria who are escalating or switching from second-generation H1 antihistamines.

  Recruiting Novartis · Kirksville, Missouri · NCT07358780

• Remibrutinib use in everyday clinical care for chronic spontaneous urticaria

  This project sees if remibrutinib helps adults with chronic spontaneous urticaria who need higher‑dose second‑generation antihistamines or are switching to remibrutinib.

  Recruiting Novartis · Kirksville, Missouri · NCT07358364

• Pelabresib plus ruxolitinib for adults with myelofibrosis

  This trial will see if adding pelabresib to ruxolitinib helps adults with primary myelofibrosis or post‑PV/post‑ET myelofibrosis who have not previously taken JAK inhibitor therapy.

  Recruiting at 165 sites Phase 3 Novartis · Denver, Colorado and 164 other locations · NCT07357727

• Asciminib for children and teens with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

  This study will try asciminib as a treatment for children aged 1 to under 18 with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase, including newly diagnosed patients and those who are resistant or intolerant to prior TKIs, with or without the T315I mutation.

  Recruiting at 39 sites Phase 2 Novartis · Chicago, Illinois and 38 other locations · NCT07354074

• Pelabresib drug interactions with common meds in advanced cancer

  This study tests how pelabresib affects the body’s handling of repaglinide, midazolam, and the combined oral contraceptive in adults with advanced cancers.

  Recruiting at 6 sites Phase 1 Novartis · Bordeaux and 5 other locations · NCT07340190

• Votoplam for adults with early symptomatic Huntington's disease

  This trial will test whether votoplam (HTT227) is safe and can slow disease progression in adults with early symptomatic Huntington's disease.

  Recruiting at 117 sites Phase 3 Novartis · Birmingham, Alabama and 116 other locations · NCT07326709

• Lutetium (177Lu) vipivotide tetraxetan treatment for men with metastatic prostate cancer in China

  This study will try lutetium (177Lu) vipivotide tetraxetan in men in China with metastatic prostate cancer (both castration-resistant and hormone-sensitive) to see how it is used, how patients do, and how their quality of life changes.

  Recruiting Novartis · Shanghai, Shanghai Municipality · NCT07290270

• GVV858 alone or with fulvestrant or letrozole for HR+/HER2- breast cancer and other advanced tumors

  This trial tests whether GVV858 alone or with fulvestrant or letrozole can help adults with HR+/HER2- advanced breast cancer, CCNE1‑amplified solid tumors, or metastatic castration‑resistant prostate cancer.

  Recruiting at 16 sites Phase 1/2 Novartis · Atlanta, Georgia and 15 other locations · NCT07288359

• Secukinumab outcomes in Canadians with hidradenitis suppurativa

  It will see how well secukinumab works and how safe it is for adults in Canada with moderate-to-severe hidradenitis suppurativa who were newly prescribed it in routine care.

  Recruiting at 15 sites Novartis · Calgary, Alberta and 14 other locations · NCT07282015

• Targeted radioligand [177Lu]Lu-DFC413 for advanced pancreatic, lung, breast, and colorectal cancers

  This will test a new targeted radioactive medicine, [177Lu]Lu-DFC413 (with a PET tracer [68Ga]Ga-NNS309), to see if it is safe and shows activity in adults with advanced pancreatic, lung, breast, or colorectal cancer.

  Recruiting at 9 sites Phase 1 Novartis · Princeton, New Jersey and 8 other locations · NCT07261631

• EDI048 for relieving cryptosporidiosis symptoms after controlled exposure in healthy adults

  This trial will test whether EDI048 can reduce diarrhea and other symptoms in healthy adults who are deliberately exposed to Cryptosporidium.

  Recruiting at 2 sites Phase 2 Novartis · Baltimore, Maryland and 1 other locations · NCT07249463

• Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

  This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.

  Recruiting Novartis · Seoul, Seoul · NCT07243782

• Real-world outcomes and patient experiences with early use of ribociclib

  This project will see how people with HR+/HER2- stage II–III early breast cancer do on ribociclib plus endocrine therapy and will also gather patient-reported experiences for those on abemaciclib plus endocrine therapy.

  Recruiting Novartis · London · NCT07243002

• OJR520 safety and dose testing in healthy people and adults with chronic kidney disease

  This trial will test whether OJR520 is safe, well tolerated, and how the body processes it in healthy volunteers and adults with chronic kidney disease (including diabetic CKD).

  Recruiting at 2 sites Phase 1 Novartis · Miami, Florida and 1 other locations · NCT07235059

• Real-world use of iptacopan for PNH in Italy

  This project will see if iptacopan works and is safe for adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treated in Italian clinics.

  Recruiting at 12 sites Novartis · Alessandria, AL and 11 other locations · NCT07229235

• AMO959 with Lutetium‑177 PSMA‑617 plus ARPI for PSMA‑positive metastatic castration‑resistant prostate cancer

  This trial tests whether adding the experimental drug AMO959 to lutetium‑177 PSMA therapy together with an androgen receptor pathway inhibitor can help adults with PSMA‑positive metastatic castration‑resistant prostate cancer who have already received one ARPI.

  Recruiting at 25 sites Phase 1/2 Novartis · Los Angeles, California and 24 other locations · NCT07226986

• Remibrutinib for secondary progressive multiple sclerosis

  This trial will try remibrutinib versus placebo to see if it slows disability progression in adults with secondary progressive multiple sclerosis.

  Recruiting at 296 sites Phase 3 Novartis · Birmingham, Alabama and 295 other locations · NCT07225504

• PKN605 for reducing atrial fibrillation burden

  This trial will test whether the experimental drug PKN605 can reduce the amount of time adults with atrial fibrillation spend in irregular heart rhythm compared with placebo.

  Recruiting at 38 sites Phase 2 Novartis · Tupelo, Mississippi and 39 other locations · NCT07217067

• Tulmimetostat plus luxdegalutamide for men with progressive metastatic castrate-resistant prostate cancer.

  This will test whether combining tulmimetostat (DZR123) with luxdegalutamide (JSB462) helps men with progressive metastatic castrate-resistant prostate cancer achieve better PSA responses than standard care.

  Recruiting at 35 sites Phase 1/2 Novartis · Denver, Colorado and 34 other locations · NCT07206056

• MAS825 treatment for children and adults with Still's disease

  This trial will test whether MAS825 helps children and adults with active Still's disease and is safe and tolerable.

  Recruiting at 20 sites Phase 2 Novartis · Cincinnati, Ohio and 23 other locations · NCT07203001

• Tulmimetostat with darolutamide or abiraterone for metastatic hormone-sensitive prostate cancer

  This trial will test whether adding tulmimetostat to darolutamide or abiraterone helps men with metastatic hormone-sensitive prostate cancer control their cancer better.

  Recruiting at 30 sites Phase 1/2 Novartis · Birmingham, Alabama and 30 other locations · NCT07190300

• Zigakibart treatment for IgA nephropathy

  This trial will test whether the drug zigakibart can slow disease progression in people with biopsy-confirmed IgA nephropathy and persistent proteinuria.

  Recruiting at 30 sites Phase 2 Novartis · San Francisco, California and 29 other locations · NCT07146906

• Early inclisiran after a heart attack: one-year outcomes

  This project will test whether giving inclisiran within about two weeks after a STEMI or non‑STEMI improves cholesterol control and clinical outcomes over the first year in adults with recent MI and dyslipidemia.

  Recruiting at 18 sites Novartis · Cheboksary and 17 other locations · NCT07142265

• First human testing of EDK060 in adults with CMT1A.

  This trial will test whether different doses of the experimental drug EDK060 are safe and how the body processes them in adults with CMT1A.

  Recruiting at 4 sites Phase 1 Novartis · Ottawa, Ontario and 3 other locations · NCT07140614

• First-in-human imaging test with Ga-DWJ155 in advanced breast cancer and NSCLC

  This early-phase study tests a radioactive imaging agent, 68Ga-DWJ155, to see how it distributes in the body and how well it images tumors in adults with HR+/HER2-, HER2+, or NSCLC adenocarcinoma.

  Recruiting Phase 1 Novartis · Groningen, Provincie Groningen · NCT07117214

• Early in-hospital start of inclisiran for people with acute coronary syndrome

  This study tests whether giving inclisiran soon after hospital admission helps people with acute coronary syndrome when added to standard care compared with a placebo.

  Recruiting at 27 sites Phase 3 Novartis · Capital Federal, Buenos Aires and 68 other locations · NCT07102628

• Real‑world CML patient registry looks at experiences and outcomes with first- or second-line TKI therapy

  This registry follows adults with chronic-phase CML who are on approved TKIs to see how they tolerate treatment, how safe it is, how well it works, and how patients feel over up to five years.

  Recruiting at 17 sites Novartis · Birmingham, Alabama and 16 other locations · NCT07091019

• Targeted lipid optimization program to improve LDL-C control in adults with ASCVD

  This program will test whether a targeted education-based lipid optimization program helps adults with ASCVD and high LDL-C reach recommended LDL-C targets better than usual care.

  Recruiting Phase 4 Novartis · Abu Dhabi · NCT07034690

• Home-reported outcomes for people with C3 Glomerulopathy

  This project will collect monthly home-reported symptoms, treatment use, and quality-of-life information from adults with C3 glomerulopathy and their caregivers to see how these change over time.

  Recruiting Novartis · East Hanover, New Jersey · NCT07029542

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Alpelisib for children and adults with PIK3CA-related overgrowth spectrum (PROS)

  This project will try daily oral alpelisib to see if it reduces overgrowth and improves symptoms in children and adults with PROS.

  Recruiting at 41 sites Phase 2 Novartis · Sacramento, California and 40 other locations · NCT06997588

• Iptacopan for children with primary IgA nephropathy

  This will try oral iptacopan in children aged 2 to <18 with primary IgA nephropathy to lower protein in the urine and check safety.

  Recruiting at 20 sites Phase 3 Novartis · Madera, California and 19 other locations · NCT06994845

• Mobile app to track symptoms and treatment in IgA nephropathy patients

  This study is testing a mobile app that helps people with IgA nephropathy track their symptoms and treatments to see how it affects their health and quality of life.

  Recruiting Novartis · Boston, Massachusetts · NCT06952426

• Testing new treatments for moderate to severe atopic dermatitis

  This trial will test an experimental medicine called GHZ339 (compared with placebo) to see if it reduces symptoms in people with moderate to severe atopic dermatitis.

  Recruiting at 69 sites Phase 2 Novartis · Birmingham, Alabama and 104 other locations · NCT06947993

• Iptacopan for children and teens with PNH to see how the drug behaves in the body and whether it is safe

  This trial will try oral iptacopan in children and teens (ages 2 to under 18) with PNH to see how their bodies handle the drug and whether it is safe and well tolerated.

  Recruiting at 15 sites Phase 3 Novartis · Atlanta, Georgia and 14 other locations · NCT06934967

• Iptacopan treatment for adults with PNH in China

  This study will try iptacopan (LNP023) in adults with PNH in China to see if it improves clinical and laboratory outcomes and changes healthcare use.

  Recruiting at 14 sites Novartis · Hefei, Anhui and 13 other locations · NCT06931691

• Ribociclib with hormone therapy after surgery for HR+ HER2‑negative stage II–III breast cancer in Russia

  This project will try ribociclib together with an aromatase inhibitor in adults in Russia who had surgery for HR+ HER2‑negative stage II–III breast cancer to see how well it works and how safe it is.

  Recruiting at 42 sites Novartis · Sochi, Russian Federation and 41 other locations · NCT06930859

• Gene therapy for young children with nephropathic cystinosis

  This study is testing a new gene therapy for young children aged 2 to 5 with nephropathic cystinosis to see if it works better than the usual treatment.

  Recruiting at 6 sites Phase 1/2 Novartis · Phoenix, Arizona and 5 other locations · NCT06910813

• Using a mobile app to improve sticking with ribociclib plus hormone therapy in stage II–III HR+ HER2‑ breast cancer

  This project will test whether a mobile app helps people with stage II–III HR+ HER2-negative breast cancer stick to ribociclib plus an aromatase inhibitor.

  Recruiting at 7 sites Novartis · Pskov, Russia and 6 other locations · NCT06905301

• Evaluating secukinumab effectiveness in Korean patients with ankylosing spondylitis

  This study is testing how well secukinumab works for Korean patients with ankylosing spondylitis who haven't tried other treatments before.

  Recruiting at 3 sites Novartis · Jinju, Gyeongsangnam-do and 2 other locations · NCT06905288

• Evaluating Remibrutinib for Chronic Urticaria

  This study is testing if a new medication called remibrutinib can help adults with Chronic Urticaria feel better compared to a placebo over 12 weeks.

  Recruiting at 14 sites Phase 2 Novartis · North Miami Beach, Florida and 16 other locations · NCT06865651

• Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia

  We will measure Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia and their relatives to see how common high levels are and whether they link to higher heart and stroke risk.

  Recruiting at 20 sites Novartis · Chelyabinsk and 19 other locations · NCT06858332

• Long-term zigakibart treatment for adults with IgA nephropathy

  Adults with IgA nephropathy who finished an earlier zigakibart trial will receive ongoing subcutaneous zigakibart every two weeks to see if it stays safe and helps over the long term.

  Recruiting at 26 sites Phase 3 Novartis · Denver, Colorado and 25 other locations · NCT06858319

• AAA817 (225Ac-PSMA-617) plus ARPI versus standard care for PSMA-positive metastatic castration-resistant prostate cancer

  This trial tests whether adding [225Ac]Ac-PSMA-617 (AAA817) to an androgen receptor pathway inhibitor helps people with PSMA-positive metastatic castration-resistant prostate cancer stay free of radiographic progression longer than standard treatment options.

  Recruiting at 106 sites Phase 3 Novartis · Homewood, Alabama and 105 other locations · NCT06855277

• Remibrutinib after switching from ocrelizumab for relapsing multiple sclerosis

  This study will see if remibrutinib, a daily oral BTK inhibitor, keeps relapsing MS under control in people switching from ocrelizumab compared with continuing ocrelizumab.

  Recruiting at 128 sites Phase 3 Novartis · Scottsdale, Arizona and 130 other locations · NCT06846281

• Ilaris for periodic fever syndromes and systemic juvenile idiopathic arthritis in Korea

  This will test how safe and effective Ilaris is for children and adults in Korea who are being treated for hereditary periodic fever syndromes or systemic juvenile idiopathic arthritis.

  Recruiting Novartis · Seoul · NCT06838143

• Evaluating ribociclib with aromatase inhibitors for early breast cancer treatment

  This study is testing if combining ribociclib with an aromatase inhibitor can help people with early breast cancer feel better and reduce their risk of the cancer coming back.

  Recruiting at 285 sites Novartis · Wiener Neustadt, Lower Austria and 286 other locations · NCT06830720

• Ruxolitinib for corticosteroid-refractory chronic graft-versus-host disease in Chinese patients

  This trial will try ruxolitinib in Chinese adolescents (12+) and adults whose chronic graft-versus-host disease has not improved with corticosteroids.

  Recruiting at 22 sites Phase 4 Novartis · Hefei, Anhui and 21 other locations · NCT06824103

• Ribociclib plus hormone therapy for HR+/HER2- early breast cancer in Saudi Arabia

  This study will try to see if adding ribociclib to standard adjuvant hormone therapy is effective and safe for adults in Saudi Arabia with HR+/HER2- early breast cancer.

  Recruiting at 2 sites Novartis · Riyadh and 1 other locations · NCT06797531

• Iptacopan added to standard care to change kidney biopsy findings in adults with IgA nephropathy

  This will try iptacopan added to standard treatment for adults with biopsy-confirmed IgA nephropathy to see if it reduces mesangial complement (C3c) deposits and improves kidney biomarkers over 9 months.

  Recruiting at 19 sites Phase 2 Novartis · Birmingham, Alabama and 18 other locations · NCT06797518

• Long-term follow-up registry for Kymriah (tisagenlecleucel) in South Korea

  This project will follow people in Korea with B-cell leukemias or lymphomas who received Kymriah to see if the treatment stays safe and continues to work well over many years.

  Recruiting at 18 sites Novartis · Bundang Gu, Gyeonggi-do and 17 other locations · NCT06785818

• Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

  This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

  Recruiting at 4 sites Novartis · Riyadh, SAU and 3 other locations · NCT06785779

• [177Lu]Lu-DOTA-TATE plus octreotide LAR for newly diagnosed SSTR‑positive advanced GEP‑NET

  This trial will test whether adding [177Lu]Lu‑DOTA‑TATE to octreotide LAR helps people newly diagnosed with somatostatin receptor–positive, well‑differentiated (G1/G2, Ki‑67 <10%) advanced gastroenteropancreatic neuroendocrine tumors who have a high disease burden.

  Recruiting at 66 sites Phase 3 Novartis · Scottsdale, Arizona and 66 other locations · NCT06784752

• Comparing AAA817 to Standard Care for Advanced Prostate Cancer

  This study is testing a new drug called AAA817 to see if it works better than standard treatments for adults with advanced prostate cancer that hasn't responded to other therapies.

  Recruiting at 93 sites Phase 2/3 Novartis · Scottsdale, Arizona and 92 other locations · NCT06780670

• Leqvio (inclisiran) post-marketing surveillance in Korea

  This will see if Leqvio (inclisiran) is safe and lowers LDL cholesterol for adults in Korea with primary hypercholesterolemia or mixed dyslipidemia who are prescribed it in routine care.

  Recruiting at 4 sites Novartis · Yangsan, Gyeongsangnam-do and 3 other locations · NCT06770543

• Evaluating the safety and effectiveness of intravenous secukinumab in children with juvenile psoriatic arthritis.

  This study is testing if an intravenous medication called secukinumab is safe and effective for children with juvenile psoriatic arthritis.

  Recruiting at 11 sites Phase 1 Novartis · Loma Linda, California and 10 other locations · NCT06751238

• Using eye movement biomarkers to track disease changes in active RRMS patients

  This study is testing if tracking eye movements can help doctors see how well a new treatment works for people with active Relapsing Remitting Multiple Sclerosis.

  Recruiting at 14 sites Phase 4 Novartis · Calgary, Alberta and 13 other locations · NCT06733922

• Treatment for advanced HR+/HER2- breast cancer and other solid tumors

  This study is testing a new treatment called ECI830, alone and with other medications, to see if it helps people with advanced hormone receptor-positive breast cancer and certain other solid tumors.

  Recruiting at 33 sites Phase 1/2 Novartis · Los Angeles, California and 32 other locations · NCT06726148

• Long-term follow-up of ianalumab with or without stopping treatment for people with lupus nephritis

  This 2-year extension will test whether continuing or stopping ianalumab keeps kidney disease under control and is safe for people with lupus nephritis who completed the core study.

  Recruiting at 50 sites Phase 3 Novartis · Orchard Park, New York and 52 other locations · NCT06711887

• Observational study on the effectiveness of asciminib for chronic myelogenous leukemia in Saudi Arabia

  This study is testing how well the drug asciminib works for people in Saudi Arabia with chronic myelogenous leukemia who have already tried other treatments.

  Recruiting at 4 sites Novartis · Dammam and 3 other locations · NCT06684964

• Safety of Entresto for children with chronic heart failure

  This study is testing how safe Entresto is for kids aged 1 to under 18 who are starting treatment for chronic heart failure.

  Recruiting at 26 sites Novartis · Ōbu, Aichi-ken and 27 other locations · NCT06659393

• Exploring the treatment LTP001 in healthy individuals and those with pulmonary arterial hypertension

  This study is testing a new treatment called LTP001 in healthy people and those with pulmonary arterial hypertension to see how safe it is and if it can help improve their condition.

  Recruiting at 87 sites Phase 1/2 Novartis · Scottsdale, Arizona and 86 other locations · NCT06649110

• Testing LXE408 for treating chronic Chagas disease

  This study is testing a new drug called LXE408 to see if it can effectively treat chronic Chagas disease in people who don't have severe organ problems.

  Recruiting at 21 sites Phase 2 Novartis · Sylmar, California and 21 other locations · NCT06632600

• Evaluating Inclisiran for Children with Familial Hypercholesterolemia

  This study is testing if a new medication called inclisiran can safely lower cholesterol levels in children aged 6 to under 12 who have a genetic condition that causes high cholesterol.

  Recruiting at 64 sites Phase 3 Novartis · San Francisco, California and 65 other locations · NCT06597019

• Evaluating inclisiran for children with a rare cholesterol condition

  This study is testing if a new cholesterol-lowering drug called inclisiran is safe and effective for children aged 2 to under 12 who have a rare condition that causes very high cholesterol levels.

  Recruiting at 19 sites Phase 3 Novartis · San Francisco, California and 18 other locations · NCT06597006

• Evaluating a new treatment for advanced pancreatic, lung, breast, and colorectal cancers

  This study is testing a new type of radiation treatment for people with advanced pancreatic, lung, breast, and colorectal cancers to see if it is safe and effective.

  Recruiting at 29 sites Phase 1 Novartis · Birmingham, Alabama and 28 other locations · NCT06562192

• Evaluating ITU512 for Sickle Cell Disease and Healthy Participants

  This study is testing a new drug called ITU512 to see if it is safe and effective for people with sickle cell disease and healthy adults.

  Recruiting at 13 sites Phase 1/2 Novartis · Birmingham, Alabama and 13 other locations · NCT06546670

• Evaluating the use of lutetium vipivotide tetraxetan in advanced prostate cancer

  This study is trying to see how the treatment lutetium vipivotide tetraxetan affects the quality of life for men with advanced prostate cancer over the course of their treatment and follow-up.

  Recruiting at 38 sites Novartis · Konstanz, Baden-Wurttemberg and 37 other locations · NCT06517719

• Using asciminib to treat chronic myeloid leukemia patients with a specific mutation

  This study is testing if a new drug called asciminib can help people with chronic myeloid leukemia who have a specific mutation and haven't had success with other treatments.

  Recruiting at 6 sites Phase 2 Novartis · Bordeaux and 5 other locations · NCT06514534

• Pluvicto post-marketing safety and effectiveness in Korea.

  This program will follow men in Korea with metastatic castration-resistant prostate cancer who are receiving Pluvicto to see if the treatment is safe and works in routine care.

  Recruiting at 12 sites Novartis · Seongnam-si, Gyeonggi-do and 11 other locations · NCT06514521

• Evaluating the impact of inclisiran on lowering LDL cholesterol in patients after acute cardiovascular events

  This study is testing if adding a new cholesterol-lowering medication called inclisiran to regular care can help people who have recently had a heart attack or stroke lower their LDL cholesterol levels better than just regular care alone.

  Recruiting at 10 sites Phase 4 Novartis · Corrientes and 10 other locations · NCT06501443

• Observing the effects of Ofatumumab on Multiple Sclerosis in Greece

  This study is trying to see how well Ofatumumab works for adults with Relapsing Multiple Sclerosis in Greece over two years.

  Recruiting at 14 sites Novartis · Athens, Attica and 14 other locations · NCT06486779

• Investigating Crizanlizumab for Sickle Cell Disease in Adolescents and Adults

  This study is testing if a new medication called crizanlizumab can help reduce painful episodes in adolescents and adults with sickle cell disease.

  Recruiting at 35 sites Phase 3 Novartis · Birmingham, Alabama and 35 other locations · NCT06439082

• Capturing patient experiences in Paroxysmal Nocturnal Hemoglobinuria

  This study is trying to gather information from people with Paroxysmal Nocturnal Hemoglobinuria about their symptoms and treatment experiences using a mobile app over six months to better understand their quality of life.

  Recruiting Novartis · East Hanover, New Jersey · NCT06411626

• Continued treatment with pelabresib for patients from previous studies

  This study is testing whether continued treatment with pelabresib can help people who have already tried it in earlier studies stay healthy and live longer without leukemia.

  Recruiting at 15 sites Phase 3 Novartis · Los Angeles, California and 14 other locations · NCT06401356

• Improving Psoriatic Arthritis Screening for Patients with Plaque Psoriasis

  This study is testing a new way to help doctors spot psoriatic arthritis earlier in patients with plaque psoriasis by adding extra questions and images to a screening tool.

  Recruiting at 30 sites Novartis · Calgary, Alberta and 29 other locations · NCT06382051

• Survey on the use of Revolade tablets in children with aplastic anemia

  This study is testing if Revolade tablets are safe and effective for children aged 6 to 17 with aplastic anemia who haven't received certain treatments yet.

  Recruiting at 17 sites Novartis · Nagoya, Aichi-ken and 16 other locations · NCT06287268

• Monitoring the use of Tafinlar and Mekinist in patients with specific tumors

  This study is testing how well the drugs Tafinlar and Mekinist work and how safe they are for adults and kids with certain hard-to-treat tumors.

  Recruiting at 39 sites Novartis · Nagakute, Aichi-ken and 69 other locations · NCT06262919

• Assessing the safety of Kesimpta during pregnancy for women with multiple sclerosis

  This study looks at whether using the MS drug Kesimpta during pregnancy is safe for women with multiple sclerosis compared to other treatments and no treatment at all.

  Recruiting Novartis · Basel · NCT06156683

• Long-term safety evaluation of ianalumab for systemic lupus erythematosus

  This study is testing the long-term safety of a medication called ianalumab in people with systemic lupus erythematosus who have already tried other treatments.

  Recruiting at 129 sites Phase 3 Novartis · Anniston, Alabama and 166 other locations · NCT06133972

• Long-term safety evaluation of Zolgensma in Brazilian SMA patients

  This study is looking at the long-term safety of the Zolgensma treatment in Brazilian children with Spinal Muscular Atrophy to see how it affects them over time.

  Recruiting at 2 sites Novartis · Curitiba, Paraná and 1 other locations · NCT06019637

• Assessing the effects of EYU688 on dengue fever

  This study is testing a new treatment called EYU688 to see if it can help people with dengue fever feel better and recover faster compared to a placebo.

  Recruiting at 26 sites Phase 2 Novartis · Manaus, Amazonas and 26 other locations · NCT06006559

• Treatment for lymphatic malformations with a specific genetic mutation

  This study is testing if a new targeted therapy called alpelisib can help both kids and adults with lymphatic malformations caused by a specific genetic mutation.

  Recruiting at 60 sites Phase 2/3 Novartis · Oakland, California and 60 other locations · NCT05948943

• Observational study of Asciminib in patients with Chronic Myeloid Leukemia

  This study is looking at how well Asciminib works and how safe it is for adults with Chronic Myeloid Leukemia in Korea who are using this medication as prescribed by their doctors.

  Recruiting at 17 sites Novartis · Wŏnju, Gangwon-do and 16 other locations · NCT05943522

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials run by Novartis are recruiting right now?

181, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 68 countries. The most sites are in United States (98 trials), Spain (57 trials), Germany (56 trials), Canada (51 trials), France (51 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 37, Phase 2: 28, Phase 1: 22, Phase 1/2: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →